Information Provided By: 
Fly News Breaks for March 23, 2015
VRTX
Mar 23, 2015 | 10:18 EDT
JPMorgan said Vertex's VX-661 top-line Phase 2 data was generally below expectations but should not be too surprising given recent management commentary. The firm said its thesis remains unchanged and believes few biotechs offer a comparable level of competitive dominance and substantial earnings leverage as Vertex and reiterated its Overweight rating.
News For VRTX From the Last 2 Days
There are no results for your query VRTX
